The good point I obtained from the article is that Lumos is undervalued compared with the industry just based on recent revenue, not projected revenue.
Projected revenue is not a given, but looking at the journey so far we are headed in the right direction, given we now have 2 new FDA approved products to sell in the market which includes the company's current flagship FebriDx.
LDX Price at posting:
9.3¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)